Wall Street Breakfast Podcast: Moderna's Good News Goes Bad

Moderna (MRNA) shares plunged nearly 18% Thursday and are down 3% premarket, despite positive Phase 3 results for its personalized melanoma vaccine, developed with Merck. Crown Castle (CCI) and American Tower (AMT) shares rose sharply in premarket trading amid reports that SpaceX is seeking at least 80,000 U.S. cell sites and is in discussions with major infrastructure companies.